% | $
Quotes you view appear here for quick access.

Keryx Biopharmaceuticals Inc. Message Board

  • yongchanpak yongchanpak Feb 10, 2013 11:07 AM Flag

    RUMOR: Keryx Pharmaceuticals to establish a partnership with DaVita Healthcare Partners (NYSE: DVA)

    News from MSN Money and Motley Fools TODAY:

    Possibility for Keryx Pharmaceuticals to establish a partnership with DaVita Healthcare Partners (NYSE: DVA), one of the leading providers of dialysis treatment for patients with ESRD. DaVita provides kidney dialysis treatment to 142,000 patients with chronic kidney failure. Eighty nine percent (89%) of its patient are covered under government-based healthcare programs, particularly Medicare. Since, Zerernx offers huge savings due to reduced use for IV iron and ESA, dialysis treatment providers such as DaVita would consider switching its phosphate binder treatments to patients. Bentsur pointed out that Sanofi’s generic Renvela doesn’t have the capacity to compete with the amount of cost savings offered by Zenerex.

    Data from the United States Renal Data System revealed that almost 600 million people have ESRD, as of 2010. According to the Centers for Disease Control and Prevention, one in 10 American adults or more than 20 million have some level of chronic kidney disease. The National Kidney and Urologic Diseases Information Clearing House (NKUDIC) indicate that the most common causes of kidney failure are diabetes and high blood pressure. There are more than 25.8 million people in United States that have diabetes, based on data from the American Diabetes Association. These figures show that the number of patients in need of ESRD treatments will grow in the years ahead. Given Zenerex's positive safety and efficacy results, it has great potential for growth once approved by government regulators.

    Sentiment: Strong Buy

    SortNewest  |  Oldest  |  Most Replied Expand all replies
5.86-0.34(-5.48%)Jun 24 4:00 PMEDT